CDB20:0002863 PDCD1LG2 — PDCD1

Experimentally validated in Human, Mouse; Orthology-inferred in Human, Rat, Frog, Zebrafish, Chicken, Macaque, Pig, Dog, Cow, Chimp, Horse, Marmoset, Sheep, Mouse

Title

Journal:; Year Published:

Abstract

B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism.

The Journal of experimental medicine, 2003; PubMed, Mus Musculus Pdcd1lg2 — Mus Musculus Pdcd1
ABSTRACT: B7H1 (PDL1) and B7DC (PDL2) are two new members of the B7 family that can interact with PD-1, a putative negative regulator for immune function. Recent studies have provided evidence for inhibitory functions of both members via PD-1. Meanwhile, compelling evidence exists for costimulatory function of both members. Here we demonstrate that expression of B7DC on the tumor cells promotes CD8 T cell-mediated rejection of tumor cells, at both the induction and effector phase of antitumor immunity. Moreover, B7DC binds to PD-1(-/-) cells and enhances T cell killing in a PD-1-independent mechanism. Our results demonstrate a novel pathway for B7DC to promote tumor immunity and may reconcile the apparently contradictory findings on the function of B7DC.

PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1.

International immunology, 2010; PubMed, Homo sapiens PDCD1LG2 — Homo sapiens PDCD1
ABSTRACT: The programmed death-1 (PD-1) molecule is involved in peripheral tolerance and in the immune escape mechanisms during chronic viral infections and cancer. PD-1 interacts with two ligands, PD-L1 and PD-L2. We have investigated the molecular mechanisms of PD-1 interactions with its ligands by surface plasmon resonance and cell surface binding as well as the ability of the two ligands to compete for PD-1 binding. PD-L1 and PD-L2 bound PD-1 with comparable affinities, but striking differences were observed at the level of the association and dissociation characteristics. PD-L1, but not PD-L2, had a delayed interaction reminiscent of a phenomenon of conformational transition. These mechanisms were confirmed by using PD-L1 mAbs that delayed the dissociation of PD-L1 from PD-1. This mechanism was not restricted to PD-1 binding since PD-L1 behaved in a similar manner with its second ligand, CD80. Finally, we could demonstrate that PD-L1 and PD-L2 competed for PD-1 binding and conversely, an antagonist PD-1 mAb blocked both PD-L1 and PD-L2 binding to PD-1 and strongly enhanced T-cell proliferation. These data further emphasize the differential molecular mechanisms of interaction of PD-L1 and PD-L2 with PD-1, and suggest possible new approach for the therapy of chronic infection, cancer and transplantation.
Basic Information on PDCD1LG2
Ligand Name: programmed cell death 1 ligand 2
Other Symbols: PD-L2, Btdc, PDL2, bA574F11.2, CD273, B7-DC, B7DC
Ligand Location: secreted based on hpa, uniprot, cell membrane based on perplexity, uniprot
Interactions with other Receptors for PDCD1LG2
Basic Information on PDCD1
Receptor Name: programmed cell death 1
Other Symbols: SLEB2, CD279, PD1, hSLE1, PD-1
Receptor Location: cell membrane based on perplexity, uniprot
HGNC Gene Symbol Report: PDCD1
GeneCards: PDCD1
Interactions with other Ligands for PDCD1